Clipping of news on Brazilian Culture, Law and Citizenship
 


Health

ANVISA approved medicine that treats cancer without cause hair loss

06/02/2014

This article was translated by an automatic translation system, and was therefore not reviewed by people.

 

 

transparent image

 

 

The ( National Health Surveillance Agency ) ANVISA approved a drug for the treatment of breast cancer that does not cause hair loss and causes fewer side effects than traditional chemotherapy . The action is possible because the drug acts directly on the tumor, rather than affecting all cells of the body . According to the organizers of the study , it is the first drug with this mechanism adopted in Brazil

The drug trastuzumab entansina (also called T-DM1 ) is designed for one type of advanced breast cancer , identified as HER2 positive , which corresponds to 20 % of all cases. Its use should occur when conventional treatment does not deliver more . In addition to avoiding the side effects of chemotherapy , it increases by 50 % survival time .

Young ballerina survives breast cancer, but still suffers effects of chemo

One of the coordinators of the study of medicine in Brazil , " José Luiz Pedrini , vice president of the Brazilian Society of Breast Unit , explains that the drug has an effect married .

- She has an antibody and a chemotherapeutic . To be extremely powerful , this chemotherapy could not be used alone because it would be very toxic to the body . What happens is that the antibody chemotherapy leads to the interior of the tumor cell and releases the medicine inside . "

Breast cancer : After being dumped by boyfriend, former model overcomes illness and gives a comeback

The mechanism of the drug is known as " Trojan horse " .

According to medical research done in several countries , including around a hundred Brazilian . " There are patients who participate in the study began in 2011 and continue living . Without this option , they survive for about six months because they had no choice of treatment, " he explains.

One reason for the better prognosis is that the new drug can be used for longer than traditional chemotherapy. " The existing drugs can be applied for a maximum of eight sessions because of toxicity.

 - By being less aggressive , the entansina trastuzumab can be used indefinitely . "

The application of the drug is taken every 21 days. Although the drug can increase the survival of patients , the breast tumor are HER2 positive remains incurable.

new option

Coordinator of Clinical Oncology Icesp ( Institute of Cancer of São Paulo ) , Maria del Pilar Estevez said drug classified as an "interesting " choice of treatment and said the Icesp will use it .

- "You get a line of treatment with fewer side effects , which provides higher quality of life for patients .

The approval of trastuzumab entansina was published last month by ANVISA . The product should be available in the market in three months. Further studies will determine whether the drug is also effective and safe if used in the early stages of the disease . The information is the newspaper O Estado de S. Paul .

 

Source : R7

 

Our news are taken in full from our partner sites . For this reason , we can not change their content even in cases of typos .

This article was translated by an automatic translation system, and was therefore not reviewed by people.

Important:
The JurisWay site does not interfere in the work provided by doctrine, why only reflect the opinions, ideas and concepts of their authors.


  Subjects list
 
  Copyright (c) 2006-2009. JurisWay - All rights reserved.